Logo image
Precision medicine through antisense oligonucleotide-mediated exon skipping
Journal article   Peer reviewed

Precision medicine through antisense oligonucleotide-mediated exon skipping

D. Li, F.L. Mastaglia, S. Fletcher and S.D. Wilton
Trends in Pharmacological Sciences, Vol.39(11), pp.982-994
2018
url
Link to Published Version *Subscription may be requiredView

Abstract

It has been well established that some genes contain exons that can be omitted from the mature mRNA without seriously compromising gene function, while protein-truncating or missense mutations in those exons cause serious disease. Manipulation of dystrophin gene expression through redirecting pre-mRNA processing has given accelerated approval for the treatment of Duchenne muscular dystrophy. Antisense oligomer-induced exon skipping of a selected exon can allow a catastrophically defective dystrophin gene to synthesize a truncated but functional dystrophin isoform. Targeted exon skipping could be applied to many other inherited gene disorders if the disease-causing mutation is found to occur in an exon whose loss from the mature mRNA would not completely abrogate gene function. Since genomic deletions of an in-frame exon are rare in many genes, genotype–phenotype correlations are limited to infrequent splice site mutations that lead to exon skipping.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Citation topics
1 Clinical & Life Sciences
1.255 Musculoskeletal Disorders
1.255.628 Duchenne Muscular Dystrophy
Web Of Science research areas
Pharmacology & Pharmacy
ESI research areas
Pharmacology & Toxicology
Logo image